ASX Announcement

First phase 1B trial of NK cells with IL-2 & Vactosertib

Published: 24/06/22, 10:04am (AEST)3 pages
Chimeric Therapeutics Limited
CHM:ASXHealthcare

Recent CHM Announcements

Price Sensitive only